AbbVie got off to a strong start for 2022, driven by success from Skyrizi and Rinvoq, as well as the company’s neuroscience platform that includes the company’s depression treatments and its three-pronged approach to migraine.
Moderna reported $7.2 billion in fourth-quarter revenue and full-year 2021 revenue of $18.5 billion based on sales of the company’s only marketed product, the mRNA vaccine Spikevax for COVID-19.
Abbott Laboratories beat fourth-quarter 2021 profit and sales estimates, aided by robust sales of COVID-19 test kits and strong demand for the company’s diagnostics products, but forecast lower-than-expected COVID-19 testing sales in 2022 due to uncertainties around the future of the pandemic.
Drugmakers Pfizer, BioNTech and Moderna are expected to reap billions of dollars from Covid-19 booster shots in a market that could rival the $6 billion in annual sales for flu vaccines for years to come, analysts and healthcare investors say.
Calling herself a “change agent,” GlaxoSmithKline Chief Executive Officer Emma Walmsley outlined plans to transform the pharmaceuticals business of GSK following the expected spin-off of the company’s consumer health division during an investor conference.
Amgen Inc. reported that third-quarter 2020 adjusted profit rose 17% due to stronger sales of drugs such as the osteoporosis treatment Prolia and the psoriasis medication Otezla, bucking challenges from lower drug prices and Covid-19.
Sanofi forecast a return to profit growth in 2018, but the company’s shares fell as analysts had hoped for a bigger boost from recent deals and a revamped drugs pipeline.
Eli Lilly and Company today announced its 2018 financial guidance, including low-single-digit revenue growth driven by volume from recently launched pharmaceutical products. The company also highlighted key events for 2018, including continued progress on Lilly’s pipeline.
Mylan NV raised the lower end of its 2017 forecasts as the U.S. drugmaker expects to benefit from the earlier-than-expected approval of its copycat of Teva’s blockbuster multiple sclerosis treatment Copaxone.
Teva Pharmaceutical Industries said it would miss 2017 profit forecasts due to competition in the U.S. market and weakening sales of the company’s multiple sclerosis drug Copaxone, hammering shares for the world’s largest generic medicine maker.